Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, today announced that it is presenting proprietary bioanalytical methods to characterise the in vivo pharmacokinetic profile and PK/PD relationship of its compounds, following systemic dosing in rodents.
Data presented at leading antibacterial conference
Stevenage, UK – 18 October 2017 – Auspherix Limited, the anti-infectives company meeting the urgent need for new antibiotics by developing a novel class of antibacterials, today announced that it is presenting proprietary bioanalytical methods to characterise the in vivo pharmacokinetic profile and PK/PD relationship of its compounds, following systemic dosing in rodents.
The data was presented in the poster ‘The discovery and characterisation of a novel class of broad-spectrum organogold-based antibiotics for the treatment of drug-resistant bacterial infections,’ during the 4th Annual Re-entering Antibacterial Drug Discovery and Development Summit, 18-19 October, Boston.
Auspherix’s new class of antibiotic compounds are differentiated from current antibiotics by their chemical structure and distinct antibacterial profile. Its organogold antibacterials have been shown to have rapid bactericidal (killing rather than growth inhibition) activity against Gram-negative bacteria and preliminary data show a low propensity for the emergence of resistance.
Dr Neil Miller, CEO of Auspherix, said: “Our body of in vitro and in vivo data is increasing as we progress toward identification of a pre-clinical development candidate. Developing a new class of antibiotics is very challenging but we are fully committed to contributing to the solution that will address the growing threat of resistance to existing antibiotics.”
-Ends-
Notes to Editors
About Auspherix Ltd
Auspherix is an anti-infectives company engaged in the discovery and development of a new class of organogold-based antibiotics for serious and difficult to treat, or potentially life threatening infections.
Its new class of antibiotics demonstrate potent and broad-spectrum activity against both Gram-positive and Gram-negative bacteria including many Gram-negative multi-drug resistant (MDR) strains where there is a global rising unmet medical need and large market potential.
The Company is utilising its proprietary organogold chemistry platform to build a pipeline of novel antibacterials with an initial focus on treating complicated urinary tract infections (cUTI). Auspherix pipeline comprises three structurally distinct, small molecule lead series currently in pre-clinical development.
As a private company, Auspherix is backed by experienced investors including the Australian Medical Research Commercialisation Fund (MRCF) and UK-based Touchstone Innovations plc (AIM IVO). The Company is located at the Stevenage Bioscience Catalyst facility, UK a world-leading hub for open innovation and centre for fast growing biotech, pharma and medtech businesses.
For further information please visit www.auspherix.com. Follow us on twitter @auspherix and on LinkedIn.
